Table 3. Clinically relevant on-treatment events, reasons for discontinuation and current status in patients with mutations in DASISION.

	Dasatinib 100 mg once daily, n=17	Imatinib 400 mg once daily, n=18
Clinically relevant on-treatment events, na	14	16
No MMR within 12 months	12	16
No cCCyR within 12 months	8	12
Loss of CCyR	6	4
Fivefold BCR-ABL1 increase with loss of MMR	2	1
Discontinued treatment, n	14	14
Protocol-defined disease progression	11	8
Lost MCyR	4	4
Transformed to AP/BP	4	3
Lost CHR	1	1
Increased WBC count	1	—
Death	1	—
Treatment failure	1	4
No PCyR, 12 months	—	2
No CCyR, 18 months	1	2
Other	2b	2c
Patient status (4-year minimum follow-up), n
Off treatment	14	14
Alive	8	10
Dead	6	4
On treatment	3	4
% Mutation detected at trigger plus molecular response at last analysis	90% G250Ed; 0.02% BCR-ABL1IS	80% F359Id; 1.03% BCR-ABL1IS
	40% T315Id; 0.039% BCR-ABL1IS	100% G250Ed; 11.3% BCR-ABL1IS
	80% T315Id; 0.013% BCR-ABL1IS	90% G250Ed; 7.7% BCR-ABL1IS
		20% F359Vd; 20.5% BCR- ABL1IS

Abbreviations: AP/BP, accelerated phase/blast phase; cCCyR, confirmed complete cytogenetic response; CCyR, complete cytogenetic response; CHR, complete hematologic response; DASISION, Dasatinib versus Imatinib Study in Treatment-Naive CML-CP; IS, international scale; MMR, major molecular response; MCyR, major cytogenetic response; PCyR, partial cytogenetic response; WBC, white blood cell.

^aPatients may have had multiple events.

^bOne no CyR, one lost CCyR.

^cOne poor/noncompliance, one patient request.

^dEstimated percentage of the mutation quantified in the sample.